Literature DB >> 1425449

Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP.

A Mizokami1, H Saiga, T Matsui, T Mita, A Sugita.   

Abstract

The effects of androgen and epidermal growth factor (EGF) on cell proliferation and the expression of mRNA and protein of androgen receptor (AR) were examined in an androgen-sensitive human prostatic cancer cell line, LNCaP, by Northern and Western blot analyses. The addition of 1 nM dihydrotestosterone (DHT), at which the proliferation of the cells was most stimulated, did not change the level of AR mRNA but increased the level of AR protein by reducing the turnover rate of the AR protein. EGF also stimulated the proliferation of the cells but repressed the expression of AR mRNA and protein. This repression was found to be exerted primarily at the level of transcription. When DHT and EGF were added simultaneously to the cells, the level of AR mRNA was reduced to the same degree as was accomplished by the addition of EGF alone. On the other hand, the level of AR protein increased but this increase was about 70% of that attained following the addition of DHT alone. The stimulatory effects of EGF and DHT on cell proliferation were found to be additive. These results indicate that EGF down-regulates the level of AR mRNA and thereby also that of AR protein irrespective of the presence of DHT, and that EGF stimulates the proliferation of LNCaP cells through a different pathway from that of DHT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425449     DOI: 10.1507/endocrj1954.39.235

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  6 in total

1.  Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

Authors:  I Sehgal; S Powers; B Huntley; G Powis; M Pittelkow; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 2.  [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Authors:  L Rinnab; A Hessenauer; S V Schütz; E Schmid; R Küfer; F Finter; R E Hautmann; K D Spindler; M V Cronauer
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

3.  Identification and characterization of a suppressor element in the 5'-flanking region of the mouse androgen receptor gene.

Authors:  M V Kumar; E A Jones; M E Grossmann; M D Blexrud; D J Tindall
Journal:  Nucleic Acids Res       Date:  1994-09-11       Impact factor: 16.971

4.  Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells.

Authors:  Y Mizuno; T Hosoi; S Inoue; A Ikegami; M Kaneki; Y Akedo; T Nakamura; Y Ouchi; C Chang; H Orimo
Journal:  Calcif Tissue Int       Date:  1994-04       Impact factor: 4.333

5.  Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.

Authors:  M V Cronauer; C Nessler-Menardi; H Klocker; K Maly; A Hobisch; G Bartsch; Z Culig
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Progression of androgen-sensitive mouse tumor (Shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone.

Authors:  N Sato; Y Watabe; H Suzuki; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1993-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.